Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
MIRA Pharmaceuticals, Inc. ( (MIRA) ) has provided an announcement.
MIRA Pharmaceuticals has released new preclinical data on SKNY-1, a drug candidate for weight loss and smoking cessation, developed by SKNY Pharmaceuticals, which MIRA is in the process of acquiring. The data, generated by Eurofins laboratories, highlights SKNY-1’s unique receptor binding and signaling profile, potentially offering therapeutic benefits without the central nervous system side effects seen in previous drugs. SKNY-1’s selective CB1 receptor modulation, CB2 receptor activity, and MAO-B inhibition suggest it could effectively address metabolic syndrome and addiction issues while maintaining emotional stability. The company is finalizing in vivo studies to further evaluate SKNY-1’s efficacy, which will guide future development and regulatory plans.
The most recent analyst rating on (MIRA) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on MIRA Pharmaceuticals, Inc. stock, see the MIRA Stock Forecast page.
More about MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing innovative drug candidates for weight loss and smoking cessation. The company is in the process of acquiring SKNY Pharmaceuticals, Inc., which is developing SKNY-1, a next-generation oral drug candidate.
Average Trading Volume: 1,242,045
Technical Sentiment Signal: Hold
For detailed information about MIRA stock, go to TipRanks’ Stock Analysis page.